CAR-T therapy targets autoimmune diseases, but trial never started
NCT ID NCT06869278
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LCAR-AIO CAR-T cells (a type of genetically modified immune cell)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like multiple sclerosis or myasthenia gravis.
What could go wrong
This trial was withdrawn before enrolling anyone, so no results exist. CAR-T therapy can cause severe side effects, and it is very early-stage research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Fujian Medical University
Fuzhou, China
-
The First Affiliated Hospital of SOOCHOW University
Suzhou, China
-
Union Hospital Tongji Medical College HUAZHONG University of Science and Technology
Wuhan, China